-
Mashup Score: 0Complete Bone Response Observed in Trial of AB8939 for AML - 1 year(s) ago
A patient who received AB8939, a microtubule inhibitor, in a phase 1 study, had a significant reduction in bone marrow blasts, showing its potential to treat drug-resistant acute myeloid leukemia.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
A phase 1/2 study showed that treatment with #AB8939, a microtubule destabilizer, resulted in a complete bone response in a patient with relapsed and refractory #AML. #leusm https://t.co/TISWrVRgqh